MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of hematology and oncology Ročník 14; číslo 1; s. 1 - 12
Hlavní autoři:	Han, Jing, Liu, Yang, Yang, Sen, Wu, Xuan, Li, Hongle, Wang, Qiming
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 05.01.2021 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Amino acids Antimitotic agents Antineoplastic agents Apoptosis Binding sites Cancer Cancer Research Cancer therapies Cell differentiation Cell proliferation Chemotherapy Diarrhea Drug resistance Drug therapy Epidermal growth factor Extracellular signal-regulated kinase FDA approval Gene mutations Genetic aspects Health aspects Hematology Hypertension Immune checkpoint inhibitors Immunosuppressive agents Kinases Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell MAP kinase Medical prognosis Medical research Medicine Medicine & Public Health Medicine, Experimental MEK MEK inhibitors Metastasis Mutation Neutropenia Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Protein-tyrosine kinase Proteins RAF Raf protein RAS Review Schedules Signal transduction Small cell lung carcinoma Targeted therapy Tumor cells Tyrosine Vomiting MEK Targeted therapy RAS MEK inhibitors RAF ERK signaling pathway Non-small cell lung cancer
ISSN:	1756-8722, 1756-8722
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	1756-8722 1756-8722
DOI:	10.1186/s13045-020-01025-7